Donate For Public and Patients Store Search

U047 - Case Controversies in the Treatment of Atopic Dermatitis

Saturday, March 2; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Design treatment regimens for difficult to treat atopic dermatitis patients.
  • Recognize that for many difficult atopic dermatitis patients, there is no "ideal" therapy and even experts have differing approaches.

Description

Have difficult or frustrating atopic dermatitis patients? Parents who don't want to use topical steroids? Patients who want 'natural' treatments? Patients who want to treat their atopic dermatitis with dietary avoidance? Patients who have failed all your normal approaches? 4 highly experienced clinicians with diverse viewpoints (a dermatologist who specializes in adult atopic dermatitis, a double boarded pediatrician/pediatric dermatologist, a double boarded allergist/dermatologist, and an allergist who specializes in atopic dermatitis) will share their approaches to challenging atopics. You will take home pearls and approaches you can use next week in your practice!

Disclosures

  • Boguniewicz, Mark, MD: Eli Lilly and Company – A(H); Regeneron Pharmaceuticals, Inc. – A(H), I(Grants/Research Funding), Speaker/Faculty Education(H); Sanofi Genzyme – A(H), Speaker/Faculty Education(H);
  • Fonacier, Luz S., MD: Pfizer Inc. – I(Grants/Research Funding); Regeneron – A(H), I(Grants/Research Funding); Shire – I(Grants/Research Funding);
  • Gehris, Robin P., MD: no financial relationships exist with commercial interests.
  • Zirwas, Matthew, MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Asana Biosciences, LLC – I(Grants/Research Funding); Aseptic MD – SH(ST); ChemoCentryx – I(Grants/Research Funding); DS Laboratories – I(Grants/Research Funding); Foamix – I(Grants/Research Funding); Genentech, Inc. – C(H); Incyte Corporation – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); L'Oreal USA Inc. – C(H); LEO Pharma, US – I(Grants/Research Funding); Lilly ICOS LLC – I(Grants/Research Funding); Menlo Therapeutics – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Pfizer Inc. – I(Grants/Research Funding); Regeneron – SP(H); Sanofi – SP(H); UCB – I(Grants/Research Funding);
Schedule
Saturday, March 2
4:30 PM
All faculty / Case Controversies in the Treatment of Atopic Dermatitis
Event Details
  • Date
    Saturday, March 2
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 102B
  • CME Credits
    1.00
  • Type
    New
Directors/Co-Directors
Speakers
  • Luz S. Fonacier, MD
  • Mark Boguniewicz, MD
  • Robin P. Gehris, MD, FAAD